Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | FLT1 | P17948 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506402 | 0.90 | HSP90AA1 (0.52) | HSP90AA1KDRPDGFRBHSP90AB1HDAC6 | |
| SCHEMBL14506405 | 0.90 | HSP90AA1 (0.43) | HSP90AA1KDRPDGFRBHSP90AB1EGFR | |
| SCHEMBL14506410 | 0.87 | HSP90AA1 (0.44) | HSP90AA1KDRPDGFRBHSP90AB1EGFR | |
| SCHEMBL14506411 | 0.81 | HSP90AA1 (0.45) | HSP90AA1KDRPDGFRBHSP90AB1EGFR | |
| SCHEMBL14506401 | 0.79 | HSP90AA1 (0.54) | HSP90AA1KDRPDGFRBHSP90AB1HDAC6 | |
| SCHEMBL14453502 | 0.78 | HSP90AA1 (0.58) | HSP90AA1KDRPDGFRBHSP90AB1EGFR | |
| SCHEMBL13539725 | 0.76 | HSP90AA1 (0.47) | HSP90AA1KDRPDGFRBHSP90AB1EGFR | |
| SCHEMBL14506517 | 0.76 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL13539721 | 0.75 | HSP90AA1 (0.68) | HSP90AA1KDRPDGFRBHSP90AB1EGFR | |
| SCHEMBL14506407 | 0.74 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1HDAC6HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885KDR 4114/4885PDGFRB 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.